Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT07127289

Autologous Hematopoietic Stem Cell Infusion for Prolonged Cytopenia After CAR-T Cell Therapy

Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-08-17

20

Participants Needed

1

Research Sites

156 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a prospective, single-arm, single-center clinical study designed to evaluate the safety of autologous hematopoietic stem cell infusion for the treatment of prolonged cytopenia following CAR-T cell therapy. Approximately 20 patients will be enrolled.

CONDITIONS

Official Title

Autologous Hematopoietic Stem Cell Infusion for Prolonged Cytopenia After CAR-T Cell Therapy

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Ability to understand and willingly sign a written informed consent form
  • Age 18 years or older
  • Diagnosis of multiple myeloma according to International Myeloma Working Group criteria
  • Prior CAR-T cell therapy with current remission or refractory/progressive disease not needing salvage therapy
  • Presence of grade 3-4 cytopenia (low neutrophils, platelets, or hemoglobin) persisting or newly developed between day 30 and day 90 after CAR-T infusion, or suitable for inclusion by investigator judgment
  • Availability of at least 1 million autologous hematopoietic stem cells in reserve
Not Eligible

You will not qualify if you...

  • Known intolerance, hypersensitivity, or contraindication to autologous hematopoietic stem cell infusion
  • Active hepatitis B or hepatitis C infection
  • Known HIV infection
  • Life expectancy less than 6 months
  • Women who are pregnant or breastfeeding
  • Evidence of uncontrolled dysfunction of heart, lung, brain, or other important organs
  • Any other conditions deemed unsuitable for the trial by the principal investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences

Tianjin, Tianjin Municipality, China

Actively Recruiting

Loading map...

Research Team

G

Gang An, PhD&MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here